Following media attention, $20K hospital bill lowered to $200

Media spotlighting of extraordinarily high hospital bills can pay off for patients on the hook for thousands of dollars after a hospital visit. Such is the case for one San Francisco resident who was stuck with a bill for more than $20,000—after her insurance paid its part—following a bicycle accident.

Nina Dang was treated at Zuckerberg San Francisco General Hospital last April after the accident, and the hospital bill she later received revealed the broader, aggressive billing practices of the medical center, which is the largest public hospital in San Francisco. Surprisingly, the hospital––which was renamed after Facebook founder and CEO Mark Zuckerberg gave a $75 million donation––does not contract with any private insurance provider, Vox uncovered.

That leaves patients who have private insurance with out-of-network bills if they receive services at Zuckerberg General, and about one-third of all ambulances in the city bring patients there. Vox’s reporting on Dang’s medical bill drew national attention and resulted in a dramatic reduction in the final outstanding bill––to just $200, or the regular co-payment for emergency room use under her insurance plan.

The reduction in Dang's bill is not the first time media attention has led a hospital to change its mind about what patients owe. A bill that exceeded $100,000 for a patient who received care for a heart attack was dramatically reduced after it was spotlighted by NPR in 2018.

The report also prompted the San Francisco Board of Supervisors to plan hearings on Zuckerberg General’s billing practices, Vox reported. The story was part of Vox’s ongoing investigations into hospital billing practices.

See the full story:

Amy Baxter

Amy joined TriMed Media as a Senior Writer for HealthExec after covering home care for three years. When not writing about all things healthcare, she fulfills her lifelong dream of becoming a pirate by sailing in regattas and enjoying rum. Fun fact: she sailed 333 miles across Lake Michigan in the Chicago Yacht Club "Race to Mackinac."

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.